Acadia Pharmaceuticals Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.acadia.com

Moat Score

Market Cap $3.09B
PE 24
Debt $NaN
Cash $155.15M
EV $NaN
FCF $202.66M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$128.51M
EBIT	$136.69M
ROE	22%
ROA	14%
FCF	$202.66M
Equity	$577.18M
Growth Stability	1
PE	24.08
PB	5.36
P/FCF	15.27
P/S	3.33
Price/Cash	0.05
Net Margins	12%
Gross Margins	92%
Op. Margins	15%
Sales Growth YoY	18%
Sales Growth QoQ	3%
Sales CAGR	102%
Equity CAGR	5%
Earnings Growth YoY	-150%

Earnings Growth QoQ	-2%
Sales CAGR 5Y	35%
Equity CAGR 5Y	-9%
Earnings CAGR 3Y	29%
Sales CAGR 3Y	29%
Equity CAGR 3Y	3%
Market Cap	$3.09B
Revenue	$929.24M
Assets	$976.87M
Cash	$155.15M
Shares Outstanding	165.44M
Moat Score	94%
Working Capital	444.34M
Current Ratio	2.29
Gross Profit	$851.31M
Shares Growth 3y	1%
Equity Growth QoQ	12%
Equity Growth YoY	59%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

SEC Filings

Direct access to Acadia Pharmaceuticals Inc (ACAD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acadia Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Acadia Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Acadia Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Acadia Pharmaceuticals Inc.

Years

Calculation mode

= $2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$203M	$203M	$203M	$203M	$203M	$203M	$203M	$203M	$203M	$203M	$203M	$2B
DCF		$184M	$167M	$152M	$138M	$126M	$114M	$104M	$95M	$86M	$78M	$781M
Value	$2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	TTM
Net Margins	-77K%	-270K%	-2K%	-232%	-110%	-69%	-35%	-42%	-8%	12%
ROA	-	-74%	-48%	-74%	-44%	-29%	-	-36%	-7%	14%
ROE	-	-82%	-52%	-86%	-51%	-34%	-31%	-54%	-14%	22%

Good Net Margins (11.85%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-49%	28K%	621%	79%	52%	43%	7%	40%	35%
Earnings YoY growth	-	78%	65%	7%	-15%	-4%	-29%	29%	-72%	-
Equity YoY growth	-	-35%	160%	-35%	43%	46%	-23%	-26%	8%	-9%
FCF YoY growth	-	86%	69%	4%	-22%	-10%	-17%	-10%	-115%	-